Company news from the 09/12/06 News Brief

Share this article:
MedImmune broke ground on a $250 million, multi-phase expansion project at its Frederick, MD, manufacturing site. The expansion will increase MedImmune's manufacturing capacity for monoclonal antibodies including Synagis, which it introduced to the market in 1998 and other products in the company's pipeline.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions